WASHINGTON (AP) — The maker of OxyContin says it has completed testing of an abuse-resistant version of the painkiller hydrocodone, a surprise development that could derail sales of the recently launched Zohydro, a similar medication that has been criticized for lacking such safeguards.

Purdue Pharma says it plans to submit its extended-release hydrocodone drug to the Food and Drug Administration later this year. The company’s tablets are designed to prevent users from crushing them for snorting or injection.